摘要
Idiopathic pulmonary fibrosis(IPF)is a type of interstitial lung disease,characterized by an unknown etiology,chronicity,and progressive respiratory impairment.Following IPF diagnosis,patients exhibit a median survival of only 2 to 3 years,with a staggering 70% to 80% mortality rate within 5 years[1].However,the corresponding therapeutic options remain severely limited.Presently,the efficacious treatment drugs are Pirfenidone and Nintedanib.Regrettably,these two drugs fail to substantially reverse pulmonary fibrosis,offering only a partial slowing of its progression.IPF predominantly afflicts the elderly[1],and with the aging population in China constinuously increasing,there is a compelling need to explore novel and more effective treatment strategies.
基金
financially supported by the Fundamental Research Program of Shanxi Province(202203021221238)
Research Projects of Shanxi Provincial Administration of Traditional Chinese Medicine(2023ZYYB027).
